Results 241 to 250 of about 1,016,262 (299)

Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells. [PDF]

Kaohsiung J Med Sci
Liu YC, Tseng YH, Kuan YH, Wang LY, Huang SE, Tsai SP, Yeh JL, Hsu JH.   +7 more
europepmc   +1 more source

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. [PDF]

J Exp Clin Cancer Res
Wang X, Shi Y, Shi H, Liu X, Liao A, Liu Z, Orlowski RZ, Zhang R, Wang H.   +8 more
europepmc   +1 more source

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts. [PDF]

Exp Hematol
Randall J, Evans K, Watts B, Kosasih HJ, Smith CM, Earley EJ, Erickson SW, Jocoy EL, Bult CJ, Teicher BA, de Bock CE, Smith MA, Lock RB.   +12 more
europepmc   +1 more source

Corrigendum: Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells. [PDF]

Front Pharmacol
Huang W, Yuan X, Sun T, Fan S, Wang J, Zhou Q, Guo W, Ran F, Ge Z, Yang H, Li R, Cui J.   +11 more
europepmc   +1 more source

The Synergistic Effect of Reduced Graphene Oxide and Proteasome Inhibitor in the Induction of Apoptosis through Oxidative Stress in Breast Cancer Cell Lines. [PDF]

Int J Mol Sci
Krętowski R, Szynaka B, Jabłońska-Trypuć A, Kiełtyka-Dadasiewicz A, Cechowska-Pasko M.   +4 more
europepmc   +1 more source

The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors [PDF]

Medicinal Research Reviews, 2001
AbstractThe ubiquitin‐proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here, we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various ...
Craig M. Crews, Kyung Bo Kim
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Proteasome Inhibitors

Materials and Methods, 2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
  +5 more sources

Use of Proteasome Inhibitors

Current Protocols in Immunology, 2015
AbstractProteasome inhibitors are indispensable research tools in immunology and cell biology. With numerous proteasome inhibitors available commercially, choosing the appropriate compound for a biological experiment may be challenging, especially for a novice. This unit provides an overview of the proteasome inhibitors commonly used in research.
Downey, S.L., Florea, B.I., Overkleeft, H.S., Kisselev, A.F.   +3 more
openaire   +3 more sources

Macrocyclic Proteasome Inhibitors

Current Medicinal Chemistry, 2011
Proteasome inhibitors have proven to be effective anticancer agents. Despite the success of the first on the market proteasome inhibitor bortezomib in chemotherapy, alternative clinically useful proteasome inhibitors are still urgently needed as bortezomib therapy causes severe side effects and is limited by arising drug resistance.
Krahn, D., Ottmann, C., Kaiser, Markus
openaire   +3 more sources

The proteasome and proteasome inhibitors in multiple myeloma

Cancer and Metastasis Reviews, 2017
Proteasome inhibitors are one of the most important classes of agents to have emerged for the treatment of multiple myeloma in the past two decades, and now form one of the backbones of treatment. Three agents in this class have been approved by the United States Food and Drug Administration-the first-in-class compound bortezomib, the second-generation
Sara, Gandolfi, Jacob P, Laubach, Teru, Hideshima, Dharminder, Chauhan, Kenneth C, Anderson, Paul G, Richardson   +5 more
openaire   +2 more sources